Vaxcyte, Inc. 4

CEO Grant Pickering of Vaxcyte, Inc. exercised 16,198 stock options at $2.03 and sold roughly 17,?98 Vaxcyte common shares around $55.5–$55.9 per share, including sales from children’s trusts, under a Rule 10b5-1 plan.

On July 27, 2026, Vaxcyte, Inc. CEO Grant Pickering exercised a stock option for 16,198 shares of common stock at $2.03 per share and simultaneously sold a total of 17,?98 shares (11,783 + 4,415 + 756 + 244 + 622 + 378) in multiple open-market transactions at weighted-average prices around $55.5–$55.9 per share, with the sales executed pursuant to a pre-established Rule 10b5-1 trading plan. The direct sales reduced his direct holdings from 469,445 to 453,247 shares, while his indirect holdings through children’s trusts changed modestly around the 133,000-share level per trust following small sales from each. The option exercise was in-the-money and increased his direct share count before the subsequent sales, and the filing notes that the option is fully vested and exercisable and that his holdings also include 781 shares acquired through the company’s Employee Stock Purchase Plan. Assuming an average sale price of about $55.6, the gross value of the shares sold on this date is roughly in the $950,000 range, while his remaining direct stake alone is worth approximately $25 million at those prices, indicating that the transactions represent portfolio management and liquidity rather than a wholesale reduction in ownership.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001258693-26-000015

Alert Tier

6